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Introduction: Diabetes is associated with reduced expression of heme oxygenase-1 (HO-1), a heme-degrading
enzyme with cytoprotective and proangiogenic properties. In myoblasts and muscle satellite cells HO-1 improves
survival, proliferation and production of proangiogenic growth factors. Induction of HO-1 in injured tissues
facilitates neovascularization, the process impaired in diabetes. We aimed to examine whether conditioned media
from the HO-1 overexpressing myoblast cell line can improve a blood-flow recovery in ischemic muscles of
diabetic mice.
Methods: Analysis of myogenic markers was performed at the mRNA level in primary muscle satellite cells,
isolated by a pre-plate technique from diabetic db/db and normoglycemic wild-type mice, and then cultured
under growth or differentiation conditions. Hind limb ischemia was performed by femoral artery ligation in db/db
mice and blood recovery was monitored by laser Doppler measurements. Mice were treated with a single
intramuscular injection of conditioned media harvested from wild-type C2C12 myoblast cell line, C2C12 cells
stably transduced with HO-1 cDNA, or with unconditioned media.
Results: Expression of HO-1 was lower in muscle satellite cells isolated from muscles of diabetic db/db mice when
compared to their wild-type counterparts, what was accompanied by increased levels of Myf5 or CXCR4, and decreased
Mef2 or Pax7. Such cells also displayed diminished differentiation potential when cultured in vitro, as shown by less
effective formation of myotubes and reduced expression of myogenic markers (myogenic differentiation antigen - myoD,
myogenin and myosin). Blood flow recovery after induction of severe hind limb ischemia was delayed in db/db mice
compared to that in normoglycemic individuals. To improve muscle regeneration after ischemia, conditioned media
collected from differentiating C2C12 cells (control and HO-1 overexpressing) were injected into hind limbs of diabetic
mice. Analysis of blood flow revealed that media from HO-1 overexpressing cells accelerated blood-flow recovery, while
immunohistochemical staining assessment of vessel density in injected muscle confirmed increased angiogenesis. The
effect might be mediated by stromal-cell derived factor-1α proangiogenic factor, as its secretion is elevated in HO-1
overexpressing cells.
Conclusions: In conclusion, paracrine stimulation of angiogenesis in ischemic skeletal muscle using conditioned media
may be a safe approach exploiting protective and proangiogenic properties of HO-1 in diabetes.* Correspondence: alicja.jozkowicz@uj.edu.pl
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Heme oxygenase-1 (HO-1) is an enzyme degrading heme
to three products: carbon monoxide (CO), ferrous ions
(Fe2+) and biliverdin, the latter subsequently converted to
bilirubin by biliverdin reductase. Enzymatic activity of
HO-1 attenuates oxidative stress and inflammatory reac-
tion, augments angiogenesis, increases cell survival, and
influences cell cycle [1]. The cytoprotective and anti-
apoptotic effects of HO-1 have been demonstrated in dif-
ferent cell types exposed to reactive oxygen species, proin-
flammatory cytokines, heat shock, or serum deprivation
[1]. Furthermore, HO-1 upregulates expression of vascular
endothelial growth factor (VEGF), the major proangio-
genic mediator [2], and is necessary for proper function of
stromal cell-derived factor-1α (SDF-1α), the cytokine re-
sponsible for homing of proangiogenic progenitors and
activation of mature endothelial cells [3]. Beneficial effects
of HO-1 have also been shown in cutaneous wound heal-
ing, tissues subjected to ischemia-reperfusion injury and
in transplanted organs [4-6].
Proangiogenic properties of HO-1 were shown to improve
the restoration of blood flow in ischemic skeletal muscles
and facilitate muscle regeneration [6]. Indeed, the role of
HO-1 in muscle tissue is not restricted to stimulation of
neovascularization in response to ischemia. HO-1 also influ-
ences functioning of progenitor cells - muscle satellite cells
(mSCs) and myoblasts [7] - which are responsible for forma-
tion of new myofibers after muscle degeneration or injury
[8,9]. We have shown that activation of HO-1 increases
myoblast proliferation and improves their viability in oxida-
tive stress [7]. On the other hand, constitutive activity of
HO-1 decreases myoblast differentiation via CO-dependent
inhibition of CCAAT/enhancer-binding protein-δ followed
by reduced myogenic differentiation antigen (myoD) tran-
scription, as well as through upregulation of SDF-1α and
downregulation of myomirs, the muscle-specific microRNAs
[7]. Indeed, after injection of murine myoblasts (C2C12 cell
line) overexpressing HO-1 into gastrocnemius muscle of
immunocompromized mice, the viability and proliferation
of the transplanted cells were improved but their differenti-
ation and formation of myofibers were blocked. Instead,
HO-1 overexpressing myoblasts formed hyperplastic tumors
infiltrating the surrounding tissues [7]. Hence, although
HO-1 acts as a cytoprotective and proangiogenic protein
which could be targeted to facilitate vascularization of ische-
mic muscle, especially in diabetic patients characterized by
oxidative stress and impaired angiogenesis, there is a need
to elaborate a therapeutic protocol that can minimize the
risk of adverse effects.
Diabetes is a chronic disease leading to endothelial dys-
function along with impairment of the microcirculation
[10] and inhibition of blood flow restoration after injury
[11-15]. Reduced angiogenesis also affects regeneration of
skeletal muscle in diabetic individuals [11], the processadditionally impaired by dysfunction of muscle progenitor
cells [11,16-18]. Altogether, this may cause the develop-
ment of non-healing diabetic wounds also comprising
muscle degeneration, known as diabetic ulcer syndrome,
which eventually may lead to the necessity for toe or leg
amputation [19]. Enhanced expression of HO-1 [4,20] or
SDF-1α [12,19,21] can overcome at least some deleterious
diabetic complications. However, it has not been deter-
mined so far whether the paracrine activity of myoblasts
overexpressing HO-1 may improve neovascularization of
ischemic muscles in diabetes.
In the present study, we investigated the effect of condi-
tioned media harvested from HO-1 overexpressing C2C12
myoblast cell line on blood flow recovery and muscle regener-
ation in diabetic mice subjected to hind limb ischemia (HLI).
Methods
Cell culture
Primary mSCs were isolated from normoglycemic wild-
type or diabetic db/db mice of C57BLKS background
(Taconic, Denmark, Ry), according to a pre-plate technique
[7]. Experiments were performed on pre-plate number 6,
which represented a population of muscle-derived cells
enriched in satellite cells. For a routine culture the Dulbec-
co’s modified Eagle’s medium supplemented with glucose
25 mmol/L (PAA Laboratories, Austria), supplemented
with 10% fetal calf serum (FCS; PAA Laboratories), 10%
horse serum (PAA Laboratories), penicillin (100 U/mL;
Sigma-Aldrich, USA), streptomycin (100 μg/mL; Sigma-
Aldrich) and 0.05% chicken embryo extract (Accurate
Chemicals, USA) was used. When cells reached 90 to
100% confluence, differentiation was induced by a 4-day
culture in differentiation medium (DM) - routine culture
medium containing 2% horse serum, instead of 10% fetal
calf serum and 10% horse serum. As a control, growth
medium (GM) was used, with 20% fetal calf serum.
Modified murine myoblast cells expressing control
reporter genes coding for luciferase and green fluores-
cent protein (C2C12-Luc-GFP) or additionally overex-
pressing HO-1 (C2C12-Luc-GFP-HO1), were generated
from C2C12 myoblast cell line by stable retroviral trans-
duction [7]. Cells were cultured and differentiated as
described previously [7]. Briefly, for a routine culture
and as a control GM, the Dulbecco’s modified Eagle’s
medium supplemented with glucose (25 mmol/L), 10%
fetal calf serum, penicillin (100 U/mL), and strepto-
mycin (100 μg/mL) was used. DM contained 2% horse
serum instead of 10% fetal calf serum.
To prepare conditioned media from C2C12-Luc-GFP and
C2C12-Luc-GFP-HO1 cells, the GM or DM media were
changed on EBM-2 (Lonza, Switzerland) with 0.5% fetal calf
serum, penicillin (100 U/mL) and streptomycin (100 μg/
mL) after the first or fourth day of differentiation, and
cells were cultured further for 24 hours.
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All procedures were performed in accordance with na-
tional and European legislations, after approval by the
Local Ethical Committee for Animal Experimentation in
Krakow. Animals were kept under controlled environ-
mental conditions (12-hour light/dark cycle at ~23°C),
with water and food available ad libitum.
To induce HLI, a double ligation of the superficial left
femoral artery and vein was performed in 18 male db/db
mice. Next day, animals were randomly divided into three
groups for treatment with different types of conditioned
media (six individuals per group; media in a total volume of
50 μL injected intramuscularly into three sites of ischemic
gastrocnemius muscle): i) unconditioned media (fresh
EBM-2 + 0.5% FCS); ii) conditioned media (EBM-2 + 0.5%
FCS) from differentiated C2C12-Luc-GFP cells, harvested
on the fifth day of differentiation; iii) conditioned media
(EBM-2 + 0.5% FCS) from C2C12-Luc-GFP-HO1 cells, har-
vested on the fifth day of differentiation.
The superficial blood flow of the ischemic and contra-
lateral leg was analyzed using laser Doppler Blood Perfu-
sion Imager PeriScan PIM2 (Perimed, Sweden). The
ratio between blood flow in the ischemic leg and the
contralateral leg was calculated and used as an index of
blood flow recovery. Measurements were performed be-
fore HLI (−1 day of experiment), on the day of media in-
jection (day 0) and on days 7, 14 and 28 after HLI. On
the last day of experiment animals were euthanized, and
peripheral blood, bone marrow and gastrocnemius
muscle were collected for further analyses.Blood morphology and creatine phosphokinase activity
Blood for analysis of morphology was collected from the
tail vein and analyzed with ABC Vet (Horiba ABX, Japan).
Serum was collected for analysis of creatine phosphokinase
activity, performed with the EnzyChrom Creatine Kinase
Assay Kit (BioAssays Systems, USA), according to the man-
ufacturer’s instruction.Analysis of bone marrow-derived proangiogenic
progenitor cells
Peripheral blood and bone marrow were collected and
centrifuged (400 g, 10 minutes), and erythrocytes were lysed
with Pharm Lyse (BD Bioscience, Singapore). The cell pellet
was suspended in RPMI medium (PAA Laboratories) with
2% FCS and stained with anti-Sca-1-FITC, anti-KDR-APC,
and anti-CD45-Cy7 antibodies (all diluted 1:200; BD Bio-
science) or with appropriate izotype controls for 30 mi-
nutes. Afterwards, non-conjugated antibodies were
washed out, and cells were fixed with 1% paraformalde-
hyde (POCh, Poland). CD45−Sca-1+KDR+ cells were ana-
lyzed using the LSRII flow cytometer with FACS Diva
software (BD Bioscience).Histological analysis and immunohistochemical staining
Gastrocnemius muscles were fixed in OCT freezing
medium (Leica Microsystems Germany). Sections (8 μm)
were stained with hematoxylin for 15 minutes (Sigma Al-
drich), rinsed with tap water for 15 minutes, counter-
stained with eosin (Sigma Aldrich) for 15 seconds,
dehydrated with Ottix Shaper (Diapath, Italy) for 1 minute,
Ottix Plus (Diapath) for 10 minutes, and mounted in
Canadian balsam (Paul Marienfeld GmbH, Germany).
Regenerating myofibers were analyzed in 10 different
fields of view (magnification 200×) per section.
Frozen sections for CD31 (capillaries) and α-smooth
muscle actin (αSMA; arterioles) analysis were fixed with
acetone (POCh) or 2% paraformaldeyde (POCh), respect-
ively, and blocked with 10% goat serum (Sigma Aldrich),
0.05% Tween (Sigma Aldrich), and 0.1% Triton X-100
(Sigma Aldrich) in phosphate-buffered saline. Sections
were incubated for 1.5 hours with anti-CD31 antibody
(BD Bioscience) diluted to the final concentration of
156.25 ng/mL or with anti-αSMA antibody (Abcam, UK)
diluted 1:200. Afterwards secondary antibodies conju-
gated with rhodamine (1:1000; Cappel, USA) or
Alexa488 (1:400) were applied for 45 minutes for
CD31 and αSMA staining, respectively. The number of
capillaries were analyzed in 10 different fields of view
(magnification 200×) per section, whereas the number
of arterioles were analyzed per mm2 of a section, with
ImageJ program (National Institutes of Health, USA).Gene expression analysis
Isolation of RNA from gastrocnemius muscle, bone mar-
row, and satellite cells followed by reverse transcription
and quantitative PCR were performed as previously de-
scribed [7]. Primers used in quantitative PCR reactions are
presented in Table 1.Enzyme-linked immunosorbent assay
Concentrations of SDF-1α and VEGF in conditioned
media from C2C12-Luc-GFP and C2C12-Luc-GFP-HO1
cells were measured using an enzyme-linked immuno-
sorbent assay kit (R&D Systems, USA) according to the
manufacturer’s instructions.Mass spectroscopy
Conditioned media from C2C12-Luc-GFP and C2C12-
Luc-GFP-HO1 cells were lyophilized and mass spectros-
copy was performed in triplicate with Synapt 2 HDMS
PLGS 2.4 (Waters, USA) and protein database UniProt.
The sample (800 ng) was administered on a column with
internal protein standard of yeast alcohol dehydrogenase
(50 to 75 fmol). Changes between samples were analyzed
with Waters Expression E application.
Table 1 Sequence of primers used in the research
Gene Sequence of starters
EF2 forward 5′ - GAC ATC ACC AAG GGT GTG CAG - 3′
reverse 5′ - TCA GCA CAC TGG CAT AGA GGC - 3′
HO-1 forward 5′ - GTG GAG MCG CTT YAC RTA GYG C - 3′
reverse 5′ - CTT TCA GAA GGG YCA GGT GWC C - 3′
SDF-1α forward 5′ - AAT TTC GGG TCA ATG CAC AC - 3′
reverse 5′ - GTG ACG GTA AGC CAG TCA GC - 3′
CXCR4 forward 5′ - AAA CCT CTG AGG CGT TTG GT - 3′
reverse 5′ - AGC AGG GTT CCT TGT TGG AG - 3′
CXCR7 forward 5′ - CTG AGG TCA CTT GGT CGC TC - 3′
reverse 5′ - TGC ACA GTG TCC ACC ACA AT - 3′
VEGF forward 5′ - ATG CGG ATC AAA CCT CAC CAA GGC - 3′
reverse 5′ - TTA ACT CAA GCT GCC TCG CCT TGC - 3′
VEGF-R1 forward 5′ - GCA CCT ATG CST GCA GAG C - 3′
reverse 5′ - TCT TTC AAT AAA CAG CGT GCT G - 3′
VEGF-R2 forward 5′ - CCT CAC CTG TTT CCT GTA TGG AG - 3′
reverse 5′ - GAK GCC ACA GAC TCC CTG C - 3′
Myf5 forward 5′ - CCT GTC TGG TCC CGA AAG AAC - 3′
reverse 5′ - GAC GTG ATC CGA TCC ACA ATG - 3′
MEF2 forward 5′ - CAG GCG CTA TGG GTC ATC TG - 3′
reverse 5′ - GCT ACT TGG ATT GCT GAA CTG C - 3′
myoD forward 5′ - GCT GCC TTC TAC GCA CCT G - 3′
reverse 5′ - GCC GCT GTA ATC CAT CAT GC - 3′
myogenin forward 5′ - CAG TAC ATT GAG CGC CTA CAG - 3′
reverse 5′ - GGA CCG AAC TCC AGT GCA T - 3′
myosin forward 5′ - CAC TTT GGC ACT ACG GGG AAA C - 3′
reverse 5′ - GCC ATC AGC TCT TCC TGG TCA T - 3′
Pax7 forward 5′ - CAA CCA CAT GAA CCC TGT CA - 3′
reverse 5′ - GAG ATG GAG GAA GCC GAG TC - 3′
HO-1, heme oxygenase-1; myoD, myogenic differentiation antigen; SDF-1α,
stromal cell-derived factor-1α; VEGF, vascular endothelial growth factor.
Kozakowska et al. Stem Cell Research & Therapy  (2015) 6:61 Page 4 of 16Statistical analysis
Results are expressed as mean ± standard error of the
mean. Two tailed Student’s t test was used for compari-
son of two groups, while one-way analysis of variance
with Bonferroni post-test was applied for comparison of
multiple groups.
Results
Disrupted expression of myogenic markers in muscle
satellite cells isolated from diabetic mice
Primary mSCs isolated from wild-type and db/db mice
showed the same morphology in a routine in vitro cul-
ture, but different growth characteristics; although db/db
cells reached confluence a few days earlier than their
wild-type counterparts, they formed elongated tubes less
often in a routine cell culture (Figure 1A). Accordingly,the quantitative RT-PCR analysis of gene expression re-
vealed significantly increased levels of Myf5 transcription
factor (an early marker of activated, proliferating myoblasts)
and CXCR4 receptor (associated with enhanced migration
of myoblasts and a receptor for the myogenic mitogen
SDF-1α) in cultured primary cells isolated from db/db mice
(Figure 1B). Additionally, in diabetic mSCs, reduced expres-
sion of Pax7 (the transcription factor present in quiescent
and proliferating but not in differentiating muscle progeni-
tors) was observed (Figure 1B). Also, markers characteristic
for differentiating myoblasts, namely Mef2, myoD and
myogenin, were downregulated in cells derived from dia-
betic mice in comparison to mSCs isolated from wild-type
animals (Figure 1B).
It appears, that lower expression of these myogenic differ-
entiation factors may reflect a reduced capacity of mSCs to
mature into myotubes during in vitro induced differenti-
ation (Figure 1A). The morphological assessments were
supported by analysis of differentiation markers. When cells
were cultured for 4 days in conditions that promote differ-
entiation, expression of myoD and myogenin were upregu-
lated in the wild-type cells, but not in the cells isolated
from db/db individuals (Figure 1C). Taken together, analysis
of gene expression suggests that in diabetic mice the activa-
tion and proliferation of mSCs are efficient, but differenti-
ation and formation of myotubes can be disturbed.Decreased expression of heme oxygenase-1 in muscle
satellite cells isolated from db/db mice
Regeneration of ischemic muscles depends on differenti-
ation of myoblasts, as well as on formation of new blood
vessels [22]. Both myogenesis and angiogenesis are known
to be regulated by HO-1 [1,7]. We examined the expression
of HO-1 at the mRNA level either in subconfluent primary
mSCs or in the cells subjected to differentiation. In a rou-
tine cell culture the HO-1 level showed a tendency to be
decreased in mSCs isolated from db/db mice in comparison
to that from wild-type individuals (P = 0.064; Figure 2A).
Under differentiating conditions, expression of HO-1 was
upregulated in wild-type cells (P = 0.057), whereas no such
upregulation was observed in db/db mSCs (Figure 2B).Effect of heme oxygenase-1 overexpression on
production of proangiogenic factors
In the next experiments we investigated whether forced ex-
pression of HO-1 upregulates the production of proangio-
genic growth factors in myoblasts. To obtain high and
reproducible expression of HO-1 we transduced the murine
myoblast cell line (C2C12 cells) with HO-1 transgene using
retroviral vectors. Previously we have demonstrated that
such stable overexpression of HO-1 exerted a potent effect
on differentiation, viability and proliferation of these cells
[7]. Here we have examined whether the constitutively
AWT
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Figure 1 (See legend on next page.)
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Figure 1 Muscle satellite cells (mSCs) isolated from wild-type (WT) or diabetic (db/db) mice and cultured in routine culture conditions (second and fourth
day of cell culture, growth medium (GM)) and during differentiation (fourth day of differentiation, differentiation medium (DM)). (A) Morphology of mSCs
cultured for 2 or 4 days in GM or for 4 days in DM; representative photos, magnification 100×. (B) Expression of Myf5, CXCR4, Pax7, Mef2, myoD and
myogenin mRNAs in subconfluent mSCs isolated from WT and db/db mice and cultured in GM; quantitative RT-PCR (n = 5 to 13). (C) Expression of myoD
and myogenin mRNAs in mSCs cultured for 5 days in GM or DM; quantitative RT-PCR (n = 2). EF2 served as an internal control. Each bar represents
mean + SEM. *P < 0.05, **P < 0.01, versus WT; #P < 0.05, versus cells cultured in GM. myoD, myogenic differentiation antigen.
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proangiogenic properties of C2C12 myoblasts.
We have focused on two major proangiogenic factors -
VEGF and SDF-1α. Under routine culture conditions in
GM the expression of VEGF was similar in C2C12-Luc-
GFP and C2C12-Luc-GFP-HO1 cells. Likewise, induc-
tion of myoblast maturation in DM did not affect VEGF
in control cells. Expression of VEGF mRNA was, how-
ever, decreased in differentiated myoblasts overexpress-
ing HO-1 (Figure 3A). Release of VEGF protein to the
culture medium was similarly decreased in such cells
(Figure 3B). Concomitantly, HO-1 overexpression sig-
nificantly increased production of SDF-1α, the effect es-
pecially pronounced in differentiated cells, both at
mRNA (Figure 3C) and protein (Figure 3D) levels. Thus,
media harvested from differentiated C2C12-Luc-GFP-
HO1 cells contained reduced concentrations of VEGF
(two-fold) but much higher concentrations of SDF-1α
(15-fold) than that harvested from control undifferenti-
ated C2C12-Luc-GFP cells.
To analyze secretome of C2C12 cells more comprehen-
sively we performed a mass spectroscopy analysis of condi-
tioned media harvested from differentiated C2C12-Luc-
GFP and C2C12-Luc-GFP-HO1 cells. The results showed
that overexpression of HO-1 led to complete blockage of
the release of pigment epithelium-derived factor (PEDF), a
potent inhibitor of angiogenesis (Table 2). Similar inhibition
was found for biglycan (an extracellular matrix protein
which can bind VEGF, increasing its storage or stabilizationFigure 2 Expression of heme oxygenase-1 (HO-1) mRNA in muscle satellite
(A) Subconfluent cells cultured in growth medium (GM). (B) Cells cultured
in differentiated cells (DM) is shown as a proportion of that in undifferentia
internal control. Each bar represents mean + SEM. *P < 0.05, versus WT.in the matrix and thereby regulating the VEGF signaling)
and for follistatin-related protein-1 (a protein which is sup-
posed to play a promyogenic and proangiogenic role)
(Table 2). Conditioned media harvested from C2C12-Luc-
GFP-HO1 cells also contained a reduced concentration of
fibronectin (Table 2). On the other hand, overexpression of
HO-1 resulted in induction of protein disulfide isomerase
(a protein known to stimulate neovascularization of ische-
mic tissues), and in significant upregulation of macrophage
migration inhibitory factor, peptidyl-prolyl cis-trans isomer-
ase A, haptoglobin, and galectin-1, which are associated
with enhanced angiogenesis (Table 2). Hence, mass spec-
troscopy analysis suggests that overexpression of HO-1 in-
fluences a composition of conditioned media, regulating
release of proteins related to neovascularization with a pos-
sible shift of balance toward proangiogenic factors. Some
HO-1 regulated proteins are also known to influence myo-
genesis (Table 2).
Effect of conditioned media from heme oxygenase-1
overexpressing C2C12 cells on recovery after hind limb
ischemia
Overexpression of HO-1 in C2C12 myoblasts may induce
their uncontrolled proliferation and hyperplasic growth,
along with inhibition of their differentiation after intra-
muscular transplantation [7]. To overcome this obstacle,
we investigated whether paracrine properties of HO-1
overexpressing myoblasts can improve recovery from HLI
in db/db mice. For this purpose we injected conditionedcells (mSCs) isolated from wild-type (WT) and diabetic (db/db) mice.
for 5 days in GM or differentiation medium (DM): expression of HO-1
ted cells (GM); quantitative RT-PCR (n = 11 to 13). EF2 served as an
Figure 3 Production of vascular endothelial growth factor (VEGF) and stromal cell-derived factor-1α (SDF-1α) by C2C12-Luc-GFP and C2C12-Luc-GFP-HO1
cells cultured in growth media (GM) or differentiation media (DM). (A) Expression of VEGF mRNA; quantitative RT-PCR (n = 3). (B) Secretion of VEGF protein
to conditioned media; enzyme-linked immunosorbent assay (ELISA) (n = 5). (C) Expression of SDF-1α mRNA; quantitative RT-PCR (n = 3). (D) Secretion of
SDF-1α protein to conditioned media; ELISA (n = 5). EF2 served as an internal control. Each bar represents mean + SEM; * p< 0.05 vs. C2C12-Luc-GFP cells.
#P< 0.05, versus cells cultured in GM.
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Luc-GFP-HO1 cells into the muscle of db/db mice 1 day
after femoral artery ligation. Control animals were treated
with nonconditioned medium. Measurements of blood
flow revealed an improved recovery of tissue perfusion in
diabetic mice treated with conditioned media harvested
from the HO-1 overexpressing cells. This effect was visible
at later time points, reaching statistical significance on day
28 after surgery (Figure 4A,B). Conditioned media from
C2C12-Luc-GFP cells were not effective and the kinetics
of blood flow restoration was similar to control mice
(Figure 4A,B).
Elevated blood flow in mice treated with conditioned
media from HO-1 overexpressing cells was accompanied
by increased angiogenesis. The number of CD31-positive
capillaries was higher in ischemic muscles of animalstreated with C2C12-Luc-GFP-HO1 in comparison to
those treated with control media and nonconditioned
media (Figure 5A). Both arteriogenesis (assessed by ana-
lysis of αSMA-positive arterioles, Figure 5B) and myo-
genesis (assessed by analysis of regenerating muscle
fibers with centrally located nuclei, Figure 5C) were
enhanced in response to media from C2C12-Luc-GFP-
HO1 cells. However, arteriogenesis and myogenesis
were comparable in mice treated with conditioned
media harvested from either C2C12-Luc-GFP-HO1 or
C2C12-Luc-GFP cells (Figure 5B,C).
Analysis of granulocytes, monocytes and lymphocytes in
peripheral blood, performed on day 28 after injection,
showed that conditioned media did not influence the num-
ber of circulating leukocytes (Figure 6A). Mice treated with
media harvested from the HO-1 overexpressing cells had,
Table 2 Proteins which concentrations differ significantly when harvested from C2C12-Luc-GFP and C2C12-Luc-GFP-HO1
cells
Protein Fold of change
HO-1:GFP
Properties of protein Selected
referencesAngiogenesis Myogenic
Pro Anti Pro Anti
Downregulated in C2C12-Luc-GFP-HO1 cells PEDF only in GFP + [57,62]
BGN only in GFP + + [67-69]
FRP1 only in GFP + + [66,70]
Fibronectin 0.2 + + [65,71]
Upregulated in C2C12-Luc-GFP-HO1 cells PDI only in HO-1 + [72]
PPIase A 2.59 + + [58,73]
MIF 3.06 + + [59,63]
Haptoglobin 1.72 + [60]
Galectin-1 1.86 + + [61,64,74]
Mass spectroscopy analysis. Major activities related to angiogenesis and myogenesis are indicated, based on selected references. BGN, biglycan; FRP1, follistatin-related
protein 1; GFP, green fluorescent protein; HO-1, heme oxygenase-1; MIF, macrophage migration inhibitory factor; PDI, protein disulfide isomerase; PEDF, pigment epithelium
derived factor; PPIase A, peptidyl-prolyl cis-trans isomerase A.
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higher proportion of lymphocytes than those treated
with control media or media harvested from C2C12-
Luc-GFP cells. The proportion of monocytes was similar
in all groups (Figure 6B-D). Of note, we detected did no
differences in the concentration of creatine phosphoki-
nase in the blood sera, the marker of skeletal muscle de-
generation (Figure 6E).
Recently we have demonstrated [23,24] that the num-
ber of circulating proangiogenic progenitor cells (PACs;
defined as CD45−KDR+Sca-1+ [23] or KDR+CXCR4+
[24]) does not correlate with restoration of blood flow in
ischemic muscles. In accordance, in the current study
we also did not observe such a connection. On day 28 of
the experiment, the perfusion of muscle was highest in
mice treated with media from HO-1 overexpressing
cells, while similarly lower in both animals treated with
unconditioned media or that injected with conditioned
media from control cells (Figure 4). Fluorescence-
activated cell sorting analysis performed on day 28 in
the same individuals showed that the proportion of
CD45−KDR+Sca-1+ PACs in the bone marrow, as well as
their proportion and number in peripheral blood, was
higher in mice treated with conditioned media from
control cells than in two other groups (Figure 7). Simi-
larly, gene expression of VEGF and SDF-1α pathways in
the total skeletal muscle did not show any clear connec-
tion with blood flow restoration (Figure 8). Expression
of VEGF, VEGF-R2, and CXCR4 were similar in all
groups. Both groups treated with conditioned media had
lower level of VEGF-R1, while only mice treated with
conditioned media from control cells also showed re-
duced expression of SDF-1α. Mice injected with media
from HO-1 overexpressing cells showed higher levels of
CXCR7.Discussion
Functional impairment of skeletal muscles in diabetes
includes not only insulin resistance, ischemia, lipid accu-
mulation, reduced mass, force and oxidative capacity
[25], but also disturbed regeneration after injury [11,26].
The latter can be attributed, at least in part, to impaired
function of mSCs, which are less abundant in diabetic
conditions [27] and show reduced activation as well as
weakened differentiation into mature myotubes [16].
Diabetic mSCs can induce pathological adipogenesis in-
stead of myogenesis [17] and are more prone to oxida-
tive stress [18]. Molecular characteristics of differences
between diabetic mSCs and their healthy counterparts in
the context of myogenic markers has not yet been
examined.
To the best of our knowledge, we have revealed for
the first time that mSCs of db/db mice express less Pax7
and MEF2 - transcription factors associated with quies-
cent mSCs [8,9]. On the contrary, Myf5 and CXCR4
characteristic for activated mSCs [8,9] were elevated in
cell cultures of primary mSCs isolated from diabetic in-
dividuals. Interestingly, mSCs of db/db mice have de-
creased expression of the major differentiation markers
myoD and myogenin [8,9], which proves their impaired
differentiation potential. This, together with a higher
growth rate of diabetic mSCs observed in our cell cul-
tures, could be attributed to elevated expression of
CXCR4, the major receptor for SDF-1α which is a po-
tent mitogen for mSCs [28,29].
It was shown previously that during in vivo regeneration
of diabetic muscle, 5 days after injury the myogenin ex-
pression in skeletal muscle tissue was inhibited [26], as
well the number of myoD+ cells being diminished [11].
This may be a consequence of disturbed function of dia-
betic mSCs revealed in our experiments.
Figure 4 Regeneration of blood flow after hind limb ischemia in db/db mice treated with conditioned media from C2C12-Luc-GFP, C2C12-Luc-GFP-HO1
cells or nonconditioned control media. (A) Quantitative analysis of blood flow (n = 5 to 6). Each point represents mean ± SEM; *P< 0.05, versus control.
(B) Representative pictures showing blood flow analysis (dark blue = low blood flow, red = high blood flow). Laser Doppler measurements.
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eration of diabetic muscle after injury is strictly accom-
panied by impaired revascularization and lower capillary
density in db/db mice [11]. This correlation is not surpris-
ing, since myogenesis and angiogenesis during muscle re-
generation influence each other. Formation of new blood
vessels and muscle fibers occur simultaneously [30], and
regeneration of a destroyed muscle involves tissue revas-
cularization [22]. Moreover, more than 80% of muscle
progenitor cells are not further than 20 μm from capillar-
ies, and the higher the vascularization of the muscle is, the
more mSCs are present [31]. Such a high co-localisationwas not even evident between mSCs and nuclei of mature
muscle cells [31].
Angiogenesis may be induced by mSCs and myoblasts,
which secrete proangiogenic growth factors [31,32].
Proangiogenic properties are also characteristic for HO-
1, since its activation may stimulate production and
activity of VEGF and SDF-1α [1-3,33,34]. Injection of
HO-1 overexpressing mesenchymal stem cells into is-
chemic heart improved neovascularization [35]. Recently
we have shown similar effects after injection of plasmid
encoding hypoxia-regulated HO-1 into hind limb muscle
after a femoral artery ligation procedure [6]. Importantly,
Figure 5 Histological and immunohistochemical analysis of ischemic muscles in hind limbs of db/db mice injected with conditioned media from
C2C12-Luc-GFP, C2C12-Luc-GFP-HO1 cells or nonconditioned control media, performed on day 28 after injection of media (by quantitative analysis).
(A) Angiogenesis – number of capillaries per microscopic field of view; immunohistochemical staining for CD31. (B) Arteriogenesis – number of
arterioles per mm2; immunohistochemical staining for α-smooth muscle actin. (C) Myogenesis – percentage of regenerating fibers with centrally
located nuclei; hematoxylin and eosin staining. Each point represents an individual animal. *P < 0.05, versus control; #P < 0.05, versus C2C12-Luc-GFP.
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blood flow restoration in wounded skin or ischemic
muscles of diabetic mice [4,24].
Acellular therapies, exploiting conditioned media from
HO-1 overexpressing cells, have so far been shown to in-
duce angiogenic activities of endothelial cells [2], protect
kidneys from damage after cisplatine treatment [36], or
induce neovascularization in ischemic heart [34]. Condi-
tioned media were also beneficial in the treatment of
diabetic wounds [37] and regeneration of blood flow
after ischemia in diabetic mice [24] more effectively than
were the cells. However, whether it is important to pro-
vide high expression of HO-1 in cells producing the con-
ditioning media that is subsequently used for treatment
of ischemic diabetic muscle, and whether the therapeutic
effect is stable, remain so far unexamined. Answering
these questions was the aim of our study.
Conditioned media used for experiments were prepared
from myoblasts of the C2C12 cell line, modified to overex-
press control genes (Luc and GFP) or additionally HO-1
[7]. A cell line-based model was chosen since production of
cytokines is thought to be more reproducible between cell
cultures than between cultures of primary mSCs. Condi-
tioned media used for experiments were collected from
myoblasts differentiating C2C12 cells, since the maturing
mSCs display proangiogenic properties [31]. Accordingly,
we have observed elevated levels of SDF-1α during differen-
tiation. The media were injected into gastrocnemius muscle
of db/db mice, following double femoral artery and vein
ligation and induction of ischemia.
Media harvested from C2C12-Luc-GFP-HO1 cells
promoted angiogenesis and improved blood flow in is-
chemic muscle to a higher extent than did the control
media. In animals treated in this manner the blood flowwas continuously improving throughout the time course
of the experiment and, on day 28, was at the same level
as in the intact leg. In accordance, lack of HO-1
hampers blood flow regeneration in ischemic heart of
diabetic mice [38], whereas its induction improves neo-
vascularization in the heart of healthy animals [33]. In
mice treated with unconditioned media or media from
C2C12-Luc-GFP cells, blood flow was recovering during
the first 2 weeks of the experiment; at that point the
perfusion of the ischemic leg was stable and reached
only 50% to 60% of values typical in intact muscle.
Interestingly, a similar disturbance in neoangiogenesis
with decreased capillary density leading to reduced blood
flow 14 days after HLI surgery was described previously
in diabetic mice [15,39,40]. Healthy individuals were able
to improve blood flow throughout a 4-week experiment,
reaching values of perfusion close to normal on day 28
[15,39,40]. On this basis, we suppose that the paracrine
effect of HO-1 overexpression in C2C12 myoblasts im-
proves blood vessel regeneration in db/db mice to the
same extent as in wild-type, normoglycemic mice
[15,39,40]. Disturbances in blood flow regeneration of
diabetic animals were observed in comparison to hetero-
zygotic db+/db− mice as well, although with slightly dif-
ferent kinetics of blood flow recovery and complete
restoration after 4 weeks [41,42]. The reasons for this
could be technical differences, since HLI can be per-
formed only by femoral artery ligation [41,42], femoral
artery ligation and excision of additional artery branches
[15,39,40], and femoral and vein ligation (as in our ex-
periments), which can possibly affect the level of blood
flow restoration.
Treatment of ischemic muscle with conditioned media
from C2C12-Luc-GFP-HO1 cells significantly induced
Figure 6 Parameters associated with inflammation and muscle degeneration analyzed on day 28 in peripheral blood of db/db mice injected
with conditioned media from C2C12-Luc-GFP, C2C12-Luc-GFP-HO1 cells or non-conditioned control media. (A) Number of leukocytes.
(B) Percentage of granulocytes. (C) Percentage of lymphocytes. (D) Percentage of monocytes. (E) Activity of creatine phosphokinase (CPK) in
blood serum. Each bar represents mean + SEM (n = 5 to 6). *P < 0.05, versus control. WBC, white blood cell.
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injected with unconditioned media, as indicated by the
increased number of regenerating myofibers. Interest-
ingly, similar enhancement, which did not reach statis-
tical significance, was also observed in the case ofanimals treated with media conditioned by C2C12-Luc-
GFP cells. It can be hypothesized that such an effect of
myoblast-conditioned media can be attributed to growth
factors, which are known to be secreted by these cells
(for instance, from fibroblast growth factor [43] or
Figure 7 Proangiogenic progenitor cells (PACs), defined as CD45−
KDR+Sca-1+ cells, analyzed on day 28 in peripheral blood and bone
marrow of db/db mice injected with conditioned media from C2C12-
Luc-GFP, C2C12-Luc-GFP-HO1 cells or nonconditioned control media.
(A) Percentage of PACs in bone marrow. (B) Percentage of PACs in
peripheral blood. (C) Number of PACs in peripheral blood.
Fluorescence-activated cell sorting analysis. Each bar represents
mean + SEM (n = 5 to 6). *P < 0.05, versus control, #P < 0.05, versus
C2C12-Luc-GFP. WBC, white blood cell.
Kozakowska et al. Stem Cell Research & Therapy  (2015) 6:61 Page 12 of 16insulin-like growth factor [44] families). They are able to
induce proliferation and/or differentiation of myoblasts
in a paracrine manner [43,44] and therefore can also en-
hance regeneration.
It is worth mentioning that the proposed therapeutic ap-
proach did not induce inflammatory reaction. Interestingly,
we observed a decreased percentage of granulocytes in
blood after treatment of ischemic muscle with C2C12-Luc-
GFP-HO1 conditioned media. This seems to be in accord-
ance with the anti-angiogenic role of neutrophils during
wound healing in db/db mice [45,46], evidenced for example
by the inverse correlation between neutrophil accumulation
in injured tissue and the number of new blood vessels [47].
Moreover, in contrast to implantation of modified
myoblasts engineered to overexpress HO-1, which may
lead to uncontrolled proliferation without differentiation
[7], the conditioned media strategy did not result in for-
mation of hyperplasic tissue. Thus, this method seems
to be safer than a cell-transplantation approach.
Muscle progenitor cells secrete VEGF [31,32,48], which
is a main growth factor responsible for mSC-induced
angiogenesis both in vitro [32] and in vivo [49], and also
after ischemia [48]. VEGF is a key player regulating devel-
opment of a proper microcirculation system in skeletal
muscle [50]. Its expression was reported to be lowered in
diabetic animals leading to disturbed neovascularization
[14]. However, VEGF is not responsible for observed
in vivo induction of angiogenesis in our experimental set-
ting, since its expression was unchanged between muscles
injected with C2C12-Luc-GFP and C2C12-Luc-GFP-HO1
conditioned media. Additionally, expression of VEGF in
C2C12 cells overexpressing HO-1 cultured under differen-
tiating conditions was even decreased.
On the other hand, we have previously shown that
myoblasts overexpressing HO-1 secrete more SDF-1α
[7]. In this study we have confirmed that expression and
secretion of SDF-1α is increased in C2C12-Luc-GFP-
HO1 cells, especially during differentiation. This cyto-
kine is a well known proangiogenic factor, and HO-1 is
necessary for its proper action [3,33,36]. SDF-1α stimu-
lates proliferation and migration of mature endothelial
cells, inducing them to form tube-like structures [3].
The mechanisms of these actions involves phosphoryl-
ation of cytoskeletal vasodilator-stimulated phosphopro-
tein, for which the proper level of CO obtained due to
HO-1 activity is critical [3]. Additionally, SDF-1α is
known to stimulate expression of E-selectin, inducing
adhesion of endothelial cells and formation of capillaries
[51]. Dysfunction of SDF-1α secretion may lead to ham-
pered neovascularization of ischemic muscle in diabetic
mice [21].
We suppose that SDF-1α could be a main factor in
C2C12-Luc-GFP-HO1 conditioned media improving the
induction of neovascularization in ischemic muscle of db/
Figure 8 Level of VEGF, SDF-1a and their receptors in ischemic muscle. Expression of (A) VEGF, (B) VEGF-R1, (C) VEGF-R2, (D) SDF-1α, (E) CXCR4,
and (F) CXCR7 mRNAs in gastrocnemius muscle of db/db mice subjected to hind limb ischemia and injected with conditioned media from
C2C12-Luc-GFP, C2C12-Luc-GFP-HO1 cells or nonconditioned control media. Quantitative RT-PCR performed at day 28 after injection of media
(n = 5 to 6). EF2 served as an internal control; *P < 0.05, **P < 0.01, versus control. SDF-1α, stromal cell-derived factor-1α; VEGF, vascular endothelial
growth factor.
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where transplantation of myoblasts overexpresssing SDF-
1α upregulated angiogenesis and improved functional pa-
rameters [52]. Cell therapy with fibroblasts overexpressing
SDF-1α also facilitated wound healing by induction of
neovascularization [51].
Apart from regulating angiogenesis at the level of ma-
ture endothelial cells, HO-1 and SDF-1α also increase
migration of proangiogenic progenitor cells into a
wound site, and decrease their apoptosis while increas-
ing proliferation and migration, thereby accelerating re-
generation of the microcirculation [3,20,24]. Exogenous
SDF-1α injected intramuscularly [53], delivered by a
gene transfer to mature muscle cells [54], or introduced
ex vivo into proangiogenic progenitors before transplant-
ation [55] also improved neovascularization in ischemic
skeletal muscles. Importantly, decreased mobilization of
PACs observed in diabetes [14,15] can be caused by de-
creased HO-1/SDF-1α expression [12,21] or by impaired
response to SDF-1α [12,13]. This may result in impaired
neovascularization during wound healing [12] and re-
generation of blood flow in ischemic skeletal muscle
[13,21]. It was also shown that exogenous SDF-1α im-
proved mobilization and migration of PACs, leading to
accelerated healing of diabetic wounds [12], whereas ac-
tivation of the HO-1/SDF-1α pathway enhanced PAC
mobilization and promoted re-endothelialization of the
carotid artery in diabetic mice [56].
Our experiment does not allow us to evaluate the effect of
conditioned media on mobilization of PACs at early time
points after ischemia. Analysis performed at day 28 did not
show, however, any association between PACs in bone mar-
row or peripheral blood and restoration of blood flow. It
cannot be excluded that such a relationship could be present
soon after induction of ischemia, where mobilization of
proangiogenic progenitors from the bone marrow is most
pronounced [12,15,21,51]. Nevertheless, in our earlier study
performed in hyperglycemic mice with normal or reduced
expression of HO-1, we did not observe any connection be-
tween circulating PACs and tissue reperfusion at early time
points [24].
SDF-1α is not the only possible mediator of paracrine
effects of HO-1 overexpressing C2C12 cells on blood flow
recovery in ischemic muscles. Mass spectrometry analysis
of the composition of conditioned media harvested from
C2C12-Luc-GFP and C2C12-Luc-GFP-HO1 cells revealed
other secreted proteins which might facilitate neovascular-
ization. In media from HO-1 overexpressing cells, concen-
trations of proagniogenic factors such as peptidyl-prolyl
cis-trans isomerase A, macrophage migration inhibitory
factor, haptoglobin and galectin-1 were increased, accom-
panied by decreased levels of the angiogenesis inhibitor
pigment epithelium-derived factor. Since they affect neo-
vascularization [57-61], these factors may also potentiallyfacilitate tumor development [58,62-64]. Importantly,
paracrine effects of HO-1 overexpression in C2C12 cells
did not lead to uncontrolled hyperplasic growth of myo-
blasts in ischemic muscle, in spite of increased prolifera-
tion and disturbed differentiation observed earlier in HO-
1 overexpressing C2C12 cells [7]. Instead, we observed a
tendency toward increased number of regenerating fibers
in muscles treated with media harvested from C2C12-luc-
GFP and C2C12-luc-GFP-HO1 cells. One could speculate
on the role of promyogenic proteins such as biglycan,
fibronectin, follistatin-related protein-1 or galactin-1
[65-67], which were elevated in conditioned media.
Conclusions
In conclusion, we have shown that overexpression of
HO-1 in myoblasts may augment paracrine proangio-
genic potential of these cells. Therapy with conditioned
media can lead to accelerated angiogenesis in ischemic
muscles of db/db mice, without inducing inflammatory
reaction and uncontrolled proliferation of myoblasts.
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